Only about 16 percent of US adolescents have been fully vaccinated against human papillomavirus (HPV) by the time they turn 13, despite national recommendations that call for vaccination at 11 to 12 years of age. Published in the Journal of Infectious Diseases, the new findings highlight the need for stronger efforts to encourage HPV vaccination and to improve immunization rates in this key age group.
Showing parents and children an educational video while they wait during a routine medical visit could lead to more people choosing HPV vaccination according to Regenstrief Institute, Indiana University School of Medicine, and IU Richard M. Fairbanks School of Public Health at IUPUI researchers. They used electronic health records and the state's immunization registry system to identify patients eligible for this intervention. Authors of the study, published in Pediatrics, note that this method could go a long way toward improving HPV vaccination rates.
Using DNA origami -- DNA-based design of precise nanostructures -- scientists at Karolinska Institutet, Sweden, in collaboration with researchers at University of Oslo, Norway, have been able to demonstrate the most accurate distance between densely packed antigens in order to get the strongest bond to antibodies in the immune system. The study, which is published in the journal Nature Nanotechnology, may be of significance to the development of vaccines and immunotherapy used in cancer.
A vaccine against fatal pregnancy malaria shows promising results in the first tests in humans. The new study conducted at the University of Copenhagen has untraditionally taken a vaccine all the way from discovery of a mechanism through development and production to clinical trials in humans.
There is a new medication that in one dose successfully protected nonhuman primates against a lethal infection of all strains of the deadly Ebola virus.
A new study explains why it is so hard to increase public vaccination levels even when evidence indicates that vaccines are safe and beneficial.
Hospitalized patients who received the flu vaccine had no increased risk of outpatient visits or hospital readmission within seven days of discharge, according to a Kaiser Permanente study published today in Mayo Clinic Proceedings.
Gaps in the logic of how we restock flu vaccines may be costing hundreds of lives, or more. A new model to tweak the gaps could save hundreds to hundreds-of-thousands of people and millions to multiple millions of dollars in medical costs.
Two groundbreaking discoveries by USC researchers could lead to medications and a vaccine to treat or prevent a hemorrhagic fever transmitted by a new tick species before it spreads across the United States.
The purpose of this review is to present available data on the efficacy and safety of the two available PCSK9 inhibitors in patients with FH, and importantly to discuss potential differences between the two drugs.A comprehensive literature search was performed to identify available data from clinical studies evaluating the impact of evolocumab or alirocumab on lipid and CV parameters in patients with FH.